DelveInsight’s, “Colorectal Cancer Pipeline Insight 2023” report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in the Colorectal Cancer pipeline landscape. It covers the Colorectal Cancer pipeline drug profiles, including Colorectal Cancer clinical trials and nonclinical stage products. It also covers the Colorectal Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
For Colorectal Cancer Emerging drugs, the Colorectal Cancer pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Colorectal Cancer pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
In the Colorectal Cancer Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Colorectal Cancer clinical trials studies, Colorectal Cancer NDA approvals (if any), and product development activities comprising the technology, Colorectal Cancer collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Key takeaways from the Colorectal Cancer Pipeline Report
- DelveInsight’s colorectal cancer pipeline analysis depicts a robust space with 150+ active players working to develop 150+ pipeline therapies.
- The leading Colorectal Cancer pipeline companies include Daiichi Sankyo Company, Mirati Therapeutics, Apollomics, Treos Bio Zrt, AskAt, Effector Therapeutics, Menarini Group, ImmunityBio, Arcus Biosciences, Abraxis Bioscience, Chia Tai Tianqing Pharmaceutical Group, Aadi, LLC, BioNTech SE, Novartis, Immunovative Therapies, Transgene, Cardiff Oncology, Genentech, Sumitomo Pharma Oncology, GamaMabs Pharma, Qilu Pharmaceutical, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., PharmaMar, Suzhou Zelgen Biopharmaceuticals, Innovent Biologics, Sinomab, Yooyoung Pharmaceutical, Amal Therapeutics, Celleron Therapeutics, Merck Sharp & Dohme Corp, Isofol Medical, Surgimab, EpicentRx, Inc, Apros Therapeutics, Eisai Co., Ltd., Puma Biotechnology, G1 Therapeutics, Mologen AG, Celyad Oncology, Jiangsu HengRui Medicine, Evelo Biosciences, Sinocelltech, Moderna Therapeutics, Sichuan Kelun Pharmaceutical Research Institute, Nektar Therapeutics, MedPacto, Karyopharm Therapeutics, Gritstone Oncology, Lumicell, Inc., IDEAYA Biosciences, Cantargia AB, NextCure, Inc., Lokon Pharma AB, Chongqing Precision Biotech Co., Ltd, Bold Therapeutics, OBI Pharma, Inc, Gritstone Oncology, IGM Biosciences, Rgenix, Inc., Precision Biologics, Inc, MacroGenics, Academia Sinica, Innovative Cellular Therapeutics, Merck KGaA, Lyell Immunopharma, and others.
- Promising Colorectal cancer pipeline therapies include Patritumab Deruxtecan, Adagrasib, Geptanolimab, PolyPEPI1018, Grapiprant, eFT508, MEN1611, Aldoxorubicin Hydrochloride, Etrumadenant, AL2846, ABI-009, RO7198457, Dabrafenib, AlloStim, TG6002, Onvansertib, BLYG8824A, Napabucasin, GM102, QL1203, CPGJ602, PM060184, Donafenib, IBI310, Spartalizumab, CMAB009, YYB101, ATP128, Vicriviroc, CXD101, Arfolitixorin, SGM-101, RRx-001, APR003, E7386, Trastuzumab, Trilaciclib, MGN1703, BBI608, CYAD-101, SHR-A1811, EDP1503, SCT-I10A, KL-140, V941, NKTR-255, TEW-7197, MGD019, KPT-8602, GRT-C901, LUM015, IDE196, CAN04, NC410, LOAd703, CEA CAR-T cells, BOLD-100, OBI-833, GRT-C903, IGM-8444, RGX-202-01, NE-201, DS-8201, GCC19CART, M 9140, LYL845, and others.
- The Colorectal Cancer Companies and academics are working to assess challenges and seek opportunities that could influence Colorectal Cancer R&D. The Colorectal Cancer pipeline therapies under development are focused on novel approaches to treat/improve Colorectal Cancer.
Request a sample and discover the recent breakthroughs happening in the Colorectal Cancer Pipeline landscape @ Colorectal Cancer Pipeline Outlook Report
Colorectal Cancer Overview
Colorectal cancer refers to cancer in the colon and/or rectum, or both. As the graphic below shows, the colon is part of the large intestine or large bowel. The rectum is the passageway that connects the colon to the anus. Most colorectal cancers develop first as polyps, which are abnormal growths inside the colon or rectum that may later become cancerous if they are not removed. Colorectal cancer (cancer of the colon or rectum) is very treatable when it is discovered early.
Recent Developmental Activities in the Colorectal Cancer Treatment Landscape
- In October 2022, Lyell Immunopharma announced that the US Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application to initiate a Phase 1 clinical trial for LYL845. Phase I trial to initially enroll patients with relapsed and/or refractory metastatic or locally advanced melanoma and subsequently expand into non-small cell lung cancer and colorectal cancer.
- In September 2022, Agenus announced the initiation of a global Phase II program of botensilimab, an Fc-enhanced anti-CTLA-4 that activates innate and adaptive immune responses. These trials include ACTIVATE-Colorectal, a Phase II study designed to evaluate botensilimab as monotherapy and in combination with balstilimab (anti-PD-1) for the treatment of microsatellite stable colorectal cancer.
- In September 2022, BioNTech announced that the first colorectal cancer patient had been treated with its individualized mRNA cancer vaccine BNT122 (autogene cevumeran, RO7198457) in a Phase II clinical trial.
- In August 2022, ALX Oncology initiated the Phase II clinical trial of evorpacept plus Erbitux (cetuximab) and Keytruda (pembrolizumab) in refractory microsatellite stable metastatic colorectal cancer (mCRC) patients. The combination treatment is intended for mCRC patients who have advanced following a minimum of two lines of systemic therapy.
- In August 2022, Celyad Oncology announced that the US Food and Drug Administration (FDA) lifted the clinical hold on the CYAD-101-002 (KEYNOTE-B79) Phase 1b trial after the Company made changes to the eligibility criteria for the trial.
- In June 2022, Exelixis announced the initiation of STELLAR-303, a Phase III pivotal trial evaluating XL092 in combination with atezolizumab versus regorafenib in patients with metastatic colorectal cancer (CRC) that is not microsatellite instability-high or mismatch repair-deficient, who have progressed after or are intolerant to the standard of care therapy.
For further information, refer to the detailed Colorectal Cancer Drugs Launch, Colorectal Cancer Developmental Activities, and Colorectal Cancer News, click here for Colorectal Cancer Ongoing Clinical Trial Analysis
Colorectal Cancer Emerging Drugs Profile
- Patritumab Deruxtecan: Daiichi Sankyo Company
Patritumab deruxtecan (HER3-DXd, U3-1402) is one of three lead DXd antibody drug conjugates (ADC) in the oncology pipeline of Daiichi Sankyo. Designed using Daiichi Sankyo’s proprietary DXd ADC technology, patritumab deruxtecan is comprised of a human anti-HER3 antibody attached to a topoisomerase I inhibitor payload, an exatecan derivative, via a stable tetrapeptide-based cleavable linker.
- Adagrasib: Mirati Therapeutics
Adagrasib (MRTX849) is an investigational, highly selective and potent, oral small molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. Currently, the drug is in Phase III stage of clinical trial evaluation to treat colorectal cancer.
- Etrumadenant: Arcus Biosciences
Etrumadenant (AB928), the first dual A2a/A2b adenosine receptor antagonist in the clinic, is designed to maximally inhibit the adenosine-driven impairment of tumor-infiltrating lymphocytes (mainly CD8+ T cells and NK cells) and myeloid cells (dendritic cells, macrophages), mediated by A2aR and A2bR, respectively. A2bR is also upregulated by certain cancer cells, such as in prostate cancer and KRAS- mutated cancers. As a result, etrumadenant may uniquely block adenosine’s immunosuppressive and cancer cell-intrinsic effects.
- AL2846: Advenchen Laboratories
AL2846 is a c-Met receptor tyrosine kinase (RTK) inhibitor and it also inhibits other RTKs of Flt4, KDR, Axl and Ron being developed by Advenchen Laboratories. Currently, the drug is in Phase I/II stage of clinical trial evaluation to treat colorectal cancer.
- Onvansertib: Cardiff Oncology
Onvansertib is a First-In-Class, Third-Generation, Oral and Highly-Selective PLK1 Inhibitor. The drug is in phase 1/2 of clinical trials for the treatment of patients with colorectal cancer.
Colorectal Cancer Pipeline Therapeutics Assessment
There are approx. 150+ key companies which are developing the therapies for Colorectal Cancer. The companies which have their Colorectal Cancer drug candidates in the most advanced stage, i.e. phase III include, Mirati Therapeutics.
Find out more about the Colorectal Cancer Pipeline Segmentation, Therapeutics Assessment, and Colorectal Cancer Emerging Drugs @ Colorectal Cancer Treatment Landscape
Scope of the Colorectal Cancer Pipeline Report
- Coverage- Global
- Colorectal cancer Companies- Daiichi Sankyo Company, Mirati Therapeutics, Apollomics, Treos Bio Zrt, AskAt, Effector Therapeutics, Menarini Group, ImmunityBio, Arcus Biosciences, Abraxis Bioscience, Chia Tai Tianqing Pharmaceutical Group, Aadi, LLC, BioNTech SE, Novartis, Immunovative Therapies, Transgene, Cardiff Oncology, Genentech, Sumitomo Pharma Oncology, GamaMabs Pharma, Qilu Pharmaceutical, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., PharmaMar, Suzhou Zelgen Biopharmaceuticals, Innovent Biologics, Sinomab, Yooyoung Pharmaceutical, Amal Therapeutics, Celleron Therapeutics, Merck Sharp & Dohme Corp, Isofol Medical, Surgimab, EpicentRx, Inc, Apros Therapeutics, Eisai Co., Ltd., Puma Biotechnology, G1 Therapeutics, Mologen AG, Celyad Oncology, Jiangsu HengRui Medicine, Evelo Biosciences, Sinocelltech, Moderna Therapeutics, Sichuan Kelun Pharmaceutical Research Institute, Nektar Therapeutics, MedPacto, Karyopharm Therapeutics, Gritstone Oncology, Lumicell, Inc., IDEAYA Biosciences, Cantargia AB, NextCure, Inc., Lokon Pharma AB, Chongqing Precision Biotech Co., Ltd, Bold Therapeutics, OBI Pharma, Inc, Gritstone Oncology, IGM Biosciences, Rgenix, Inc., Precision Biologics, Inc, MacroGenics, Academia Sinica, Innovative Cellular Therapeutics, Merck KGaA, Lyell Immunopharma, and others.
- Colorectal Cancer Pipeline- Patritumab Deruxtecan, Adagrasib, Geptanolimab, PolyPEPI1018, Grapiprant, eFT508, MEN1611, Aldoxorubicin Hydrochloride, Etrumadenant, AL2846, ABI-009, RO7198457, Dabrafenib, AlloStim, TG6002, Onvansertib, BLYG8824A, Napabucasin, GM102, QL1203, CPGJ602, PM060184, Donafenib, IBI310, Spartalizumab, CMAB009, YYB101, ATP128, Vicriviroc, CXD101, Arfolitixorin, SGM-101, RRx-001, APR003, E7386, Trastuzumab, Trilaciclib, MGN1703, BBI608, CYAD-101, SHR-A1811, EDP1503, SCT-I10A, KL-140, V941, NKTR-255, TEW-7197, MGD019, KPT-8602, GRT-C901, LUM015, IDE196, CAN04, NC410, LOAd703, CEA CAR-T cells, BOLD-100, OBI-833, GRT-C903, IGM-8444, RGX-202-01, NE-201, DS-8201, GCC19CART, M 9140, LYL845, and others.
- Colorectal Cancer Pipeline Segmentation: Product Type, Molecule Type, Route of Administration, Mechanism of Action
Dive deep into rich insights for drugs for Colorectal Cancer Pipeline Companies and Therapies, click here @ Colorectal Cancer Unmet Needs and Analyst Views
Table of Content
- Introduction
- Executive Summary
- Colorectal Cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Colorectal Cancer – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Adagrasib: Mirati Therapeutics
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Patritumab Deruxtecan: Daiichi Sankyo Company
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- BI 905711: Boehringer Ingelheim
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- AM 401: Altamira Therapeutics
- Drug profiles in the detailed report…..
- Inactive Products
- Colorectal Cancer Key Companies
- Colorectal Cancer Key Products
- Colorectal Cancer- Unmet Needs
- Colorectal Cancer- Market Drivers and Barriers
- Colorectal Cancer- Future Perspectives and Conclusion
- Colorectal Cancer Analyst Views
- Colorectal Cancer Key Companies
- Appendix
Got Queries? Find out the related information on Colorectal Cancer Mergers and acquisitions, Colorectal Cancer Licensing Activities @ Colorectal Cancer Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09193216187
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/